Joe Nolan is a results-focused pharma growth leader with more than 30 years of experience building high-performance teams, driving operational efficiency, and growing products in competitive spaces. In his career, Mr. Nolan helped launch several products in the central nervous system space, with the majority in orphan and specialty settings. Mr. Nolan currently serves as Chief Executive Officer of Jaguar Gene Therapy (“Jaguar”), where he has been working since early 2020. Jaguar is advancing an initial pipeline that targets diseases with significant unmet need in sizeable patient populations, starting with Type 1 Galactosemia, disorders with a Shank 3 mutation or Deletion, and Type 1 Diabetes. Jaguar leverages its unparalleled expertise and best-in-class manufacturing process, producing the purest, most effective gene therapy products, using a scalable and commercially viable manufacturing process from the outset. Thus far, Jaguar has raised over $280 million in capital. Prior to his CEO role at Jaguar, Mr. Nolan was General Manager of AveXis from 2018-2020, where he launched Zolgensma® for the treatment of spinal muscular atrophy, one of just two approved gene therapies in the U.S. at that time. Novartis then purchased AveXis for $8.7 billion. Prior to AveXis, Mr. Nolan served as the President of Dohmen Life Sciences from 2016-2018 (now Eversana) and Chief Commercial Officer for Lundbeck (2006-2014), specializing in Neurology and Psychiatry. He holds an MBA from the University of Notre Dame and currently lives outside Chicago. Mr. Nolan currently sits on the following boards: Athersys, Inc. (Public), Axovia Therapeutics (Private) and Jaguar Gene Therapy (Private).